About us

Remute Bio was started in 2015 to develop a therapeutic solution for autosomal dominant genetic diseases. We are now ready to translate our technology from discovery to preclinical and clinical application. Using a single platform technology, serious genetic illnesses can be targeted and cured, potentially providing first-in-class solutions to thousands of patients worldwide.

Remute Bio Team

Otto Kanzler, CEO and co-founder Remute Bio GmbH

Otto Kanzler, CEO and co-founder

Otto Kanzler is working in process- and business development in the biotech industry for more than 35 years now. Since 2007 he is serving as Management Consultant for production and technology-development for biotech and pharma-industry, specified for strategic and economic issues. Between 1993 and 2007 he was department head at Boehringer Ingelheim Austria, responsible for the economic issues of the industrial biopharmaceutical business. Prior to this he was head of process development for biopharmaceutical processes at Boehringer Ingelheim Austria. Otto Kanzler is a serial entrepreneur having founded and co-founded several companies, all of which are still active.

Matthias Hackl, scientific advisor and co-founder Remute Bio GmbH

Matthias Hackl
Scientific advisor and co-founder

Matthias Hackl graduated in the area of Biotechnology from the University of Natural Resources and Life Sciences Vienna (Boku) in 2012. His studies of microRNA function in mammalian cell lines and model systems of Ageing involved rotations through labs at the University of Georgia and Minnesota in the United States as well as University Bielefeld in Germany. Matthias has won two private company grants for developing applications of PCR and Flow Cytometry based microRNA quantification tools and was honored by the Austrian Association of Molecular Life Sciences and Biotechnology for his achievements during his PhD. He has authored more than 40 publications, 3 patents, and two book chapters in the field of microRNA biology and held a one-year PostDoc position in microRNA-based cell engineering at the Vienna Institute of Biotechnology before co-founding TAmiRNA in 2013, where he currently serves as Chief Executive Officer.

Johannes Grillari, scientific advisor and co-founder Remute Bio GmbH

Johannes Grillari
Scientific advisor and co-founder

Johannes Grillari has been working as associate professor and group leader at the Department of Biotechnology / University of Natural Resources and Life Sciences Vienna, Austria since 2006. His research has focused on getting insights into molecular mechanisms that trigger the onset of cellular aging and age-associated diseases. During his scientific career Johannes Grillari has authored and co-authored more than 100 research articles in SCI journals, several book chapters, 10 patents and was invited speaker to more than 120 international meetings. He is also co-founder of Evercyte GmbH, where he is Chief Scientific Officer as well as TAmiRNA GmbH and Phoenestra GmbH , where he offers his experience as scientific advisor.

Manfred Schuster, scientific advisor and co-founder Remute Bio GmbH

Manfred Schuster
Scientific advisor and co-founder

Dr. Schuster has some twenty years of experience in pharmaceutical and biotech industry. He studied technical chemistry, biotechnology and food technology at the Technical University Vienna and earned his Ph.D. in biotechnology at the University of Natural Resources and Life Sciences, Vienna, Austria. He also studied pharmaceutical quality management at the University of Vienna and is certified as QP. He was with APEIRON Biologics AG from 2005 until 2015 as COO and co-founder. In this function he built up the company and developed an enzyme substitution therapy from the idea until an exclusive license deal of € 250 M with Glaxo-SmithKline in Phase II and an orphan antibody-based immuno-therapy against neuroblastoma until submission for market approval in Europe. Manfred Schuster is also co-founder of RMB Research GmbH, where he also serves as Chief Executive Officer.

Regina Grillari, scientific advisor and co-founder Remute Bio GmbH

Regina Grillari
Scientific advisor and co-founder

Regina Grillari is associate professor for cellular biology since 2008 leading a group focused on the establishment of human in vitro cell cultures at the Department of Biotechnology, University of Natural Resources and Life Sciences Vienna, Austria. During this time her group has shown that human life span extended cell cultures that have retained their original primary like functions are valuable model systems for in vitro testings, as well as novel hosts for the production of complex biopharmaceuticals. Additionally, a method was established that allows the reprogramming of urine-derived cells towards induced pluripotent stem cells. Regina Grillari has authored and co-authored more than 60 scientific publications and book chapters, and 5 patents. She is also co-founder of Evercyte GmbH, where she serves as Chief Technology Officer as well as TAmiRNA GmbH and Phoenestra GmbH, where she offers her expertise as scientific advisor.

Scientific Resources

Huntingtin and the molecular pathogenesis of Huntington’s disease. Landles, Ch., Bates G.P. EMBO Rep. 2004 Oct; 5(10): 958–963. doi: 10.1038/sj.embor.7400250, PMCID: PMC1299150

Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Wiegman A, Gidding SS, et al, Eur Heart J. 2015 Sep 21; 36(36): 2425–2437. Publ. online 2015 May 25. doi: 10.1093/eurheartj/ehv157.
PMCID: PMC4576143

Scientific Resources

Huntingtin and the molecular pathogenesis of Huntington’s disease. Landles Ch, Bates GP,
EMBO Rep. 2004 Oct; 5(10): 958–963. doi: 10.1038/sj.embor.7400250, PMCID: PMC1299150
Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Wiegman A, Gidding SS, et al, Eur Heart J. 2015 Sep 21; 36(36): 2425–2437.
Publ online 2015 May 25. doi: 10.1093/eurheartj/ehv157. PMCID: PMC4576143

 

Our Partners

Get in touch: get_in_touch_icon Do you want to learn more about Remute Bio´s Targeted Expression Platform and when it is ready? Get in touch to receive more information about our technology and milestones.
 
Get in touch: get_in_touch_icon
Do you want to learn more about Remute Bio´s Targeted Expression Platform and when it is ready? Get in touch to receive more information about our technology and milestones.